News >

Emerging Agents, TKI Discontinuation Focal Points of CML Research

Brandon Scalea
Published: Monday, Oct 29, 2018

Neil P. Shah, MD, PhD

Neil P. Shah, MD, PhD

Patients with chronic myeloid leukemia(CML) who discontinue treatment on a tyrosine kinase inhibitor (TKI) may potentially achieve a durable treatment-free remission (TFR), according to long-term findings of clinical trials, including the ENESTop study.

In the study, patients with CML who sustained a deep molecular response for at least 2 years on second-line nilotinib (Tasigna) were taken off treatment. MR4.5 was determined as the response criteria to be eligible for TKI discontinuation. At a follow-up of 48 weeks, 57.9% of patients remained in TFR; after 96 weeks, 53.2% remained in TFR.

Nilotinib was restarted upon loss of major molecular response or confirmed loss of MR4.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication